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High-throughput screening techniques that analyze the metabolic endpoints of biological processes can identify
the contributions of genetic predisposition and environmental factors to the development of common diseases.
Studies applying controlled physiological challenges can reveal dysregulation in metabolic responses that may be
predictive for or associated with these diseases. However, large-scale epidemiological studies with well controlled
physiological challenge conditions, such as extended fasting periods and defined food intake, pose logistic challenges.
Culturally and religiously motivated behavioral patterns of life style changes provide a natural setting that can be used
to enroll a large number of study volunteers. Here we report a proof of principle study conducted within a Muslim
community, showing that a metabolomics study during the Holy Month of Ramadan can provide a unique opportunity
to explore the pre-prandial and postprandial response of human metabolism to nutritional challenges. Up to five
blood samples were obtained from eleven healthy male volunteers, taken directly before and two hours after
consumption of a controlled meal in the evening on days 7 and 26 of Ramadan, and after an over-night fast several
weeks after Ramadan. The observed increases in glucose, insulin and lactate levels at the postprandial time point
confirm the expected physiological response to food intake. Targeted metabolomics further revealed significant and
physiologically plausible responses to food intake by an increase in bile acid and amino acid levels and a decrease in
long-chain acyl-carnitine and polyamine levels. A decrease in the concentrations of a number of phospholipids
between samples taken on days 7 and 26 of Ramadan shows that the long-term response to extended fasting may
differ from the response to short-term fasting. The present study design is scalable to larger populations and may be
extended to the study of the metabolic response in defined patient groups such as individuals with type 2 diabetes.
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The accurate diagnosis of a diseased state relies on the in-
tegration of best research evidence with clinical expertise
and patient data [1]. Clinical parameters that are used to
describe the health condition of a patient are often defined
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unless otherwise stated.proteins that reflect the dynamics of disease-relevant bio-
chemical pathways in the body. Standard clinical chemistry
assays such as for glucose, insulin and triglyceride levels
have long been used for the diagnosis and medical manage-
ment of metabolic diseases and related co-morbidities [2,3].
However, research in the past decades have shown that
many common diseases are rather heterogeneous in many
aspects, suggesting an urgent need for better tools facilitat-
ing disease prediction and diagnostics.
Metabolomics, a high-throughput research approach
that is based on the profiling of the small molecule (me-
tabolite) composition of an organism, offers a compre-
hensive view of ideally all disease-relevant biochemicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diagnostic data [4]. The composition of the small mole-
cules (metabolites below 1500 Da) in a biological system
is determined by its genetic features, the regulation of
gene expression, protein abundance and environmental
influences [5]. Metabolomics has its value in the proxim-
ity to the molecular phenotype of a biological system [6]
and, therefore, is frequently applied to characterize the
status of an organism under specific conditions [7,8].
The recent implementation of metabolomics in human
cohort studies [9-11] has already revealed novel bio-
markers for numerous diseases [12-15]. The advantages
of metabolomic approaches have already been reported
in the identification of disease states or the monitoring
of therapy efficiency [16,17].
However, the metabolome is continuously changing due
to the multi-parametric response of the human body to
different molecular interactions, caused by food intake,
gut microbial metabolism, physical activity and other in-
trinsic as well as extrinsic factors [18]. The metabolic
markers that associate with complex diseases may not al-
ways be manifest under “standard” conditions, such as
overnight fasting. Some molecules strongly fluctuate after
food intake and therefore should be examined in the fast-
ing state. Other molecules show abnormal concentrations
as a consequence of metabolic disorders only after food
ingestion or other physiological challenges [19,20]. Post-
prandial dysmetabolism is increasingly recognized as a risk
factor for disease development and it is apparent that trad-
itional overnight-fasting blood draws may not always be
appropriate and sufficient for total risk assessment [21].
New strategies capturing the metabolic plasticity are
needed.
To understand the dynamic pattern of the human me-
tabolome under challenge conditions, implementation of
multiple time-point sampling is required [22]. However,
the majority of metabolomics-based experiments to date
were performed only after overnight fasting or under un-
controlled conditions. Implementation of an experimental
set-up with prolonged fasting times and controlled food-
intake that enables monitoring of time-resolved changes
in the postprandial metabolome is a challenging task and
requires several logistic considerations [23,24]. This is es-
pecially true when a large number of study participants
needs to be enrolled. Despite these challenges, this ap-
proach may promise an improvement in the identification
of metabolic dysfunctions indicating early disease states
that remain undetected in the fasting state and so should
be developed.
Here, we propose Ramadan fasting as a natural setting
to conduct physiological challenge experiments in large
populations under controlled conditions. During the Holy
Month of Ramadan, all around the world, Muslims are
fasting for a period of 28 days between dawn (Suhoor) andsunset (Iftar), abstaining from all eating, drinking, and
smoking for typically 13–18 hours daily. This makes
Ramadan fasting a more intense fast than the usual
overnight fast. After the Iftar prayer, the fast is often
broken in the community, which may allow for the co-
ordinated enrollment of study participants and also for
the administration of a controlled meal. Moreover, since
many Muslim patients with diabetes adhere to Ramadan
fasting, such a study may also provide information from
diseased individuals under otherwise inaccessible chal-
lenge conditions. Eventually, such a study could also
help to better understand how individuals with common
metabolic diseases can be best managed under Ramadan
fasting conditions.
In order to study the feasibility of a metabolic challenge
test during Ramadan fasting we conducted a proof-of-
principle study with the support of the Islamic Centre in
Freimann, Munich (Germany). The main objective of
our study was to obtain a better understanding of the
logistical and cultural factors that need to be addressed in
a religiously sensitive setting, to explore which metabolic
alterations occur under pre-prandial and postprandial
conditions of a prolonged day-time fast in comparison to
an overnight fast, and to investigate which effect sizes may
be expected using a comprehensive targeted metabolomics
analysis. These data will help inform power calculations




The Ramadan fasting study was conducted as a pilot
study to the HuMet study [22]. The HuMet study protocol
was approved by the ethical committee of the Technische
Universität München (#2087/08). This study conformed
with the Declaration of Helsinki. All study participants
gave written informed consent. A total of eleven healthy
male Muslim volunteers of varying BMI, age and national-
ity were enrolled at the Islamic Centre Munich in 2009.
The study design is illustrated in Figure 1a. For the fast-
breaking, study participants shared all the same meal in a
joint cantina at the mosque. Trays with identical, pre-
composed meals of substantial size were dispensed to all
study participants. Some variation in food supply may
have occurred, since for logistical reasons we could not
verify that participants did not share some food with other
members of the community who were not participating in
the study. However, we estimate that this effect was min-
imal. Meal compositions and nutrient analysis are pro-
vided in Additional file 1: Table S1. Blood samples were
collected before and after the fast-breaking at day 7 (time
points 1 and 2) and day 26 (time points 3 and 4) from in-
dividuals who fasted from dawn to sunset during the
month of Ramadan in 2009. A time interval of two hours
Figure 1 Study design (a) of the here presented pilot study, (b) of a potential future full-fledged Ramadan study. Red dots indicate
possible time points for sample collection.
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(shortly before and after the meal) was applied. An add-
itional blood sample was collected 4–8 weeks after
Ramadan (time point 5) after an overnight fast. Venous
blood samples were collected into 9 ml EDTA K2-Gel
tubes (Sarstedt, Nümbrecht, Germany), immediately
centrifuged at 2,500 g for 10 min at 20°C. The obtained
plasma was then aliquoted, frozen on dry ice and stored
at −80°C until further analysis. Because this study was de-
signed to be a proof-of-principle study, and also because
we were unsure about how far we would interfere with the
religious proceedings by doing so, no further data was col-
lected from the study participants. However, we found that
the community was very open to this kind of study, so that
collecting additional phenotype data is not expected to
pose any major obstacles in future studies.Clinical biochemistry analysis
The clinical biochemistry analysis was performed as
previously described for the HuMet study [22]. Briefly,
glucose and lactate concentrations were determined
by using the Super GL easy+ (Dr. Müller Geräte Bau,
Freital, Germany) based on an enzymatic amperomet-
ric technique. Insulin level was measured by enzyme-
linked immunosorbent assay (ELISA) (Dako #K6219,
Glostrup, Denmark). The plasma concentration of tri-
glycerides and non-esterified fatty acids (NEFAs) was
measured using an enzymatic colorimetric method
(Fluitest TG, Analyticon Biotechnologies AG, Lichtenfels,
Germany) and (NEFA-HR, Wako Chemicals GmbH,
Neuss, Germany), respectively. All of the above listed
methods were used according to the manufacturer’s
guidelines.
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The targeted metabolomics assay AbsoluteIDQ™ p180
(BIOCRATES Life Sciences AG, Innsbruck, Austria) was
applied for metabolite measurements in plasma samples.
Sample preparation and metabolite detection was per-
formed according to the AbsoluteIDQ™ assay kit instruc-
tions as previously described [25,26]. Metabolite detection
was performed by FIA – MS/MS (for carnitines and lipids)
and LC – MS/MS (for amino acid and biogenic amines)
on an API 4000 (AB Sciex) triple quadrupole mass spec-
trometer. Data evaluation was performed using the
MetIDQ™ software package, which is part of the Absolute-
IDQ™ kit. The AbsoluteIDQ™ p180 assay enables the detec-
tion of 186 metabolites including: 40 acylcarnitines (free
carnitine – C0 and acylcarnitines – Cx:y), 21 amino acids,
19 biogenic amines, 90 glycerophospholipids including
lysophosphatidylcholines (LysoPC a Cx:y) and phosphati-
dylcholines with acyl (PC aa Cx:y) or ether (PC ae Cx:y)
side chain, hexoses (H1) and 15 sphingolipids (SM Cx:y).
As previously described [25,26], the nomenclature used
for lipid metabolites refers to the Lipid Maps comprehen-
sive classification system [27]. The nomenclature for lipids
is as follows: Cx:y, where “x” denotes the number of car-
bons (C) and “y” represents the number of double bonds.
The protocol used for the analysis of bile-acids compos-
ition in the plasma samples was implemented as follows:
In-house protocols were used for the analysis of bile-acids
composition in the plasma samples. Plasma samples of
100 μl in Eppendorf tube were spiked with labeled internal
standards d4-deoxycholic acid, d4-glycochenodeoxycholic
acid, d4-glycocholic acid and d4-lithocholic acid (all in-
ternal standards were purchased from CDN Isotopes, Dr.
Ehrendorfer) to yield concentrations of 50 ng internal
standards/ ml plasma. After well mixing, the samples were
transferred into a 96-well plate. In addition to samples
from this study, 5 pooled human reference plasma sam-
ples and a series of 6 calibration samples with a concentra-
tion range of 5 to 150 ng bile acids/ ml plasma were also
pipetted into the 96-well plate. The calibration samples
were prepared by spiking certain concentrations of 12 bile
acids standards (cholic acid, ursodeoxycholic acid, cheno-
deoxycholic acid, deoxycholic acid, lithocholic acid, glyco-
cholic acid, glycochenodeoxycholic acid, glycodeoxycholic
acid, taurocholic acid, taurochenodeoxycholic acid, tauro-
deoxycholic acid and taurolithocholic acid; all bile acids
standards were purchased from Sigma-Aldrich) and la-
beled internal standards (50 ng/ml plasma) into human
plasma-free endogenous bile acids. Bile acid standards and
labeled internal standards used to spike the plasma samples
were dissolved in 50% v/v methanol containing 0.012% for-
mic acid and 5 mM ammonium acetate. These calibration
samples were applied to develop a calibration curve for an-
alyte quantifications. Human reference plasma samples,
treated like the samples of this study, served as technicalreplicates throughout the data set to assess process variabil-
ity. Besides the above mentioned samples, 100 μL of eluent
buffer and 100 μl of plasma-free endogenous bile acids
were also pipetted into the 96-well plate to serve as process
blanks. Proteins were precipitated and bile acids were ex-
tracted from the samples with 1 ml of acetonitrile. After
centrifugation, 800 μl of supernatant was transferred into
another 96-well plate for evaporation in vacuum evaporator
(Uniequip). Bile acids were analyzed with 4000 Q-Trap MS
(AB Sciex) equipped with LC (Shimadzu) for chromato-
graphic separation. Prior to analysis, the dried samples were
reconstituted with 150 μl of 50% v/v methanol containing
0.012% formic acid and 5 mM ammonium acetate. The MS
was operated in the ion spray ionization mode. Data were
acquired and processed using Analyst 1.5.1 software (AB
Sciex) and IntelliQuan MQll (AB Sciex) for the quantitative
processing. The measurement was performed in negative
ion mode with tandem MS via collision activated dissoci-
ation (CAD) with nitrogen as collision gas. Quantitative
data were acquired in the multiple reaction monitoring
(MRM) modes with specific precursor to product ion pa-
rameters for each analyte. Chromatographic separation was
achieved using a reverse-phase C18 column, Onyx Mono-
lithic, 130 Å pore size, 100 × 4.6 mm internal diameter
(Phenomenex). After injection of the 40 μl sample extract,
the column was developed with mobile phase of 10%
methanol containing 0.012% formic acid and 5 mM ammo-
nium acetate (eluent A) and 90% methanol with 0.012%
formic acid and 5 mM ammonium acetate (eluent B) in a
gradient of 30% eluent A to 95% eluent B in 10 min run
time, and then at constant eluent of 95% B for 2 min before
it gradually eluted to 70% eluent B. The total run time was
15 min at 1 ml/min flow rate. At analysis, the column
temperature was maintained constant at 30°C and the auto
sample temperature was at 4°C.
Statistical analysis
Statistical analysis was done using R version 3.0.2 (R Core
Team (2013). R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL http://www.R-project.org/). Linear
mixed effects models using log-scaled data were fitted to
the difference (MDIFF) between data of paired samples
from same individuals, before and after fasting-break, and
matched time-points of week 1 and 4 of Ramadan, re-
spectively, using the lme4 package in R (Douglas Bates,
Martin Maechler, Ben Bolker and Steven Walker (2014).
lme4: Linear mixed-effects models using Eigen and S4. R
package version 1.1-5. http://CRAN.R-project.org/packa-
ge=lme4). As fixed effect we entered the intercept and as
random effect we used the participant identifier (PID)
(model: MDIFF ~ 1 + (1|PID)). Significance was determined
using the chi-square statistic from an ANOVA, using a null
model with no intercept and the participant identifier as
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test the hypothesis that the difference between the log-
scaled metabolite concentrations is different from zero,
which is equivalent to testing the hypothesis that the fold
change of the metabolite concentrations is different from
unity. Deviation from normality of the residuals was tested
using the Shapiro-Wilk test. In cases where a deviation from
normality was observed (p < 0.05) we conducted subse-
quently a paired Wilcoxon rank sum test (also known as
‘Mann-Whitney’ test). In Tables 1 and 2 we report all nom-
inally significant associations (p < 0.05). In order to control
the false discovery rate (FDR), we apply the Benjamini and
Hochberg approach (as described in [28]) and focus the dis-
cussion on associations that have a FDRbelow 5%. The full
association data is provided as Additional file 2: Table S2
and Additional file 3: Table S3.
Results and discussion
Changes in clinical biochemistry during Ramadan
Readouts from clinical biochemistry parameters and se-
lected metabolites are presented in Figure 2. The corre-
sponding p-values of associations are reported in Table 1.
In accordance with the fasting state, glucose, lactate and
insulin levels were low before fast break (time points 1
and 3) but increased and showed much larger variability
after food intake (time points 2 and 4). In agreement with
the expected more intense fasting during Ramadan, insu-
lin and glucose levels at both Ramadan fasting time points
were also lower than those observed after the overnight
fast (time point 5). Levels of non-esterified fatty acids
(NEFAs) at both Ramadan fasting time points were signifi-
cantly higher compared to time points after food inges-
tion. Our results are in good accordance with the
previously reported NEFA fluctuation after an oral glucose
tolerance test and a meal tolerance test were applied [29].
In the fasting state, NEFAs are released from triacylglyc-
erol stored in adipocytes (lipolysis), thereby increasing in
plasma [30]. Consequently, increased postprandial insulin
concentrations induce a decrease in NEFA levels by rapid
suppression of lipolysis [31]. In the present study, we also
observed this correlation between the elevated plasma in-
sulin levels after ingestion of food and the decrease in con-
centrations of plasma NEFAs in the postprandial state.
Plasma triglyceride levels increased after food intake, but
only slightly on day 7 of Ramadan (time points 1 and 2)
and moderately on day 26 (time points 3 and 4). Previous
studies report triglyceride levels that doubled and reached
its peak around three hours after ingestion [32]. In our
study we did not observe such a strong effect, which may
in part be due to differences in sampling time in our study
and that of Coppack et al. [32], and also in part to differ-
ence in the meal composition. Overall, we find that the ob-
served changes in levels of insulin, glucose, lactate, NEFAs
and triglycerides are coherent with the pre-prandial andpostprandial conditions of the eleven subjects, especially
when considering the varying BMI, age and ethnicity of the
participants. These observations thus demonstrate the reli-
ability of our experimental setup.
Metabolomic changes associated with food intake
To monitor the global metabolic events occurring in the
body during Ramadan fast-breaking we applied targeted
metabolomics approaches for the detection and quantifica-
tion of a total of 202 metabolites. Individual data points for
all measured variables (202 metabolites and 6 parameters
determined using clinical chemistry methods) are provided
in Additional file 4: Figure S1. At a nominal significance
level of 0.05, the levels of 48 variables differed significantly
between pre- and postprandial state (Table 1). These me-
tabolites belong to different metabolic classes: amino acids,
bile acids, acylcarnitines, and polyamines. To illustrate the
direction of changes at different time points, the data were
visualized in the form of box-plots (Figure 2) and line plots
(Additional file 4: Figure S1). The levels of many amino
acids increased after food consumption, including aspara-
gine, arginine, alanine, glutamate, proline, and phenylalan-
ine. Methionine sulfoxide (Met-SO), which is an oxidation
product of methionine with reactive oxygen species (ROS)
and has been suggested as a biomarker for oxidative stress
[33], also showed a strong increase. Methionine oxidation
is part of a highly regulated machinery, controlling the
function of signaling factors under physiological challenge
conditions and conditions of oxidative stress [34]. When
the amino acids levels at time points 1 and 3 were com-
pared with the overnight fasting situation at time point 5,
asparagine, arginine and phenylalanine exhibited similar
levels, in contrast to proline and alanine, which after over-
night fasting were comparable to the post-prandial state in
Ramadan. Our observations are in good agreement with a
previous study that reported a decrease in amino acids
levels in both plasma and urine samples of subjects after a
prolonged fasting period of 36 h [35].
Under the postprandial conditions, the glycine/taurine
conjugated bile acids showed increased levels, whereas in
the pre-prandial state at time points 1 and 3 their concen-
trations were similar to those measured after on overnight
fast. Bile acids are produced from cholesterol in the liver
and stored in the gall bladder. The gall bladder contracts in
the postprandial state and releases bile acids into the intes-
tine, which are reabsorbed through the enterohepatic circu-
lation [36,37]. Thus, the postprandial plasma bile acid levels
are determined by the balance between intestinal input and
hepatic clearance. Bile acid levels were shown to increase
rapidly within 30 minutes after meal intake in the HuMet
study [22] and are in agreement with our expectations.
Not all metabolites were up-regulated after food inges-
tion. A significant decrease in the concentration of long-
chain acyl-carnitines was visible in the postprandial stage.
Table 1 Metabolites with significant differences after and before fast-breaking
Metabolite N Fold change p-value Test Significance
Insulin [U/L] 18 10.66 2.7x10−8 Mixed model Bonf
Non-esterferied fatty acids [mmol/L] 18 −3.067 9.8x10−6 Mixed model Bonf
Taurochenodeoxycholic acid 18 5.493 0.00020 Mixed model Bonf
Triglycerides [mg/dl] 18 1.187 0.00026 Mixed model FDR
Glycochhenodeoxycholic acid 18 3.823 0.00026 Mixed model FDR
Spermidine 17 −1.181 0.00039 Mixed model FDR
Taurocholic acid 18 4.751 0.00053 Wilcoxon FDR
Putrescine 17 −1.473 0.00064 Mixed model FDR
Glycodeoxycholic acid 15 5.961 0.00074 Mixed model FDR
Glycocholic acid 18 5.199 0.00090 Mixed model FDR
C14:2 18 −1.572 0.0016 Wilcoxon FDR
C3 18 1.179 0.0016 Wilcoxon FDR
Lactate [mg/dl] 18 1.560 0.0017 Mixed model FDR
C10 18 −1.361 0.0023 Wilcoxon FDR
C8 18 −1.238 0.0023 Wilcoxon FDR
Glutamate 17 1.247 0.0030 Mixed model FDR
C16:2 18 −1.420 0.0033 Mixed model sig
H1 18 1.226 0.0035 Mixed model sig
C10:1 18 −1.193 0.0040 Wilcoxon sig
C14:1 18 −1.133 0.0040 Wilcoxon sig
C14:2-OH 18 −1.189 0.0045 Wilcoxon sig
Taurodeoxycholic acid 14 6.006 0.0056 Mixed model sig
Arginine 17 1.202 0.0061 Mixed model sig
Met-SO 13 2.511 0.0066 Mixed model sig
Alanine 17 1.253 0.0067 Wilcoxon sig
Ornithine 17 1.199 0.0074 Mixed model sig
Proline 17 1.220 0.0084 Mixed model sig
alpha-AAA 17 1.424 0.0094 Mixed model sig
lysoPC a C16:0 18 1.087 0.012 Mixed model sig
Lysine 17 1.201 0.012 Mixed model sig
Leucine 17 1.162 0.012 Mixed model sig
Phenylalanine 17 1.167 0.012 Mixed model sig
Asparagine 17 1.197 0.018 Mixed model sig
C7-DC 18 −1.190 0.021 Mixed model sig
C0 18 1.071 0.021 Mixed model sig
Tyrosine 17 1.139 0.022 Mixed model sig
Isoleucine 17 1.178 0.023 Mixed model sig
C14:1-OH 18 −1.122 0.023 Mixed model sig
lysoPC a C17:0 18 1.103 0.026 Wilcoxon sig
C16:1 18 −1.067 0.027 Wilcoxon sig
PC aa C36:4 18 1.046 0.028 Mixed model sig
C12 18 −1.244 0.034 Mixed model sig
Tryptophan 17 1.126 0.040 Mixed model sig
PC aa C38:5 18 1.046 0.041 Mixed model sig
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Table 1 Metabolites with significant differences after and before fast-breaking (Continued)
PC aa C38:4 18 1.046 0.042 Mixed model sig
C16:1-OH 18 1.119 0.042 Mixed model sig
Valine 17 1.137 0.043 Mixed model sig
Citrulline 17 −1.156 0.050 Mixed model sig
N is the number of matched pairs that entered the analysis. Fold change is the ratio between the metabolite concentrations after and before the fasting-break,
based on the estimate of the mixed model. The reported (uncorrected) p-values are those of the mixed model if the Shapiro test for normality of the residual is
non-significant (p > 0.05), and that of the Wilcoxon rank test otherwise. The significance level of the association is indicated: significant after Bonferroni correction
(Bonf), at a false discovery rate of 5% (FDR), nominal at p < 0.05 (sig).
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pected since carnitine-bound fatty acids are imported
into the mitochondria for beta-oxidation and represent an
energy-source under fasting conditions. Consequently, de-
creases in long-chain acyl-carnitine levels reflect a switch of
energy metabolism from fatty acid to glucose oxidation in
agreement with the altered substrate availability in the post-
prandial state. We also observed a decrease in the levels of
the polyamines spermidine and putrescine after food inges-
tion. Dietary polyamines are absorbed shortly after a meal
by the small intestine and degraded in the gut before reach-
ing systemic circulation [38]. However, recently an associ-
ation between fasting plasma glucose and total polyamine
concentration was reported [39], which suggests a fluctu-
ation in polyamine concentrations as a response to the nu-
trition stimuli. Taken together, the observed changes in theTable 2 Metabolites that display significant differences betwe
Metabolite N Fold change
PC aa C36:6 16 1.221
Histamine 16 −1.028
PC ae C38:0 16 1.154
PC aa C36:0 16 1.121
Serotonin 16 1.109
SM C26:1 16 1.182
C3-DC (C4-OH) 16 −1.269
PC aa C36:1 16 1.193
PC aa C28:1 16 1.087
C16:2-OH 16 −1.143
PC ae C32:2 16 1.089
Chenodeoxycholic acid 16 2.014
PC ae C40:6 16 1.083
PC ae C38:2 16 1.116
PC ae C38:1 16 1.203
Ursodeoxycholic acid 15 −1.905
PC ae C36:0 16 1.094
PC aa C38:3 16 1.107
PC ae C34:0 16 1.108
SM (OH) C16:1 16 1.080
Fold change is the ratio between the metabolite concentrations observed at both t
(see Table 1 for full legend).different metabolic classes reflect the expected physiological
response of the human body to the break of the fasting
state.
Long-term changes in the metabolome during
Ramadan fasting
We also studied the influence of long-term fasting on the
human metabolic profile by comparing samples taken be-
fore fast breaking on week 1 to those on week 4, and those
taken after fast breaking on week 1 to those of week 4, re-
spectively. Overall, these changes displayed a lower level
of significance than the changes observed with respect to
fast-breaking. Twenty metabolites were significantly chan-
ged between week 1 and 4 of Ramadan, many of which
were phosphatidylcholines (PCs) (Table 2). Many of these






0.0083 Mixed model FDR
0.0086 Mixed model sig
0.010 Mixed model sig
0.013 Mixed model sig
0.022 Mixed model sig
0.026 Mixed model sig
0.031 Mixed model sig
0.031 Mixed model sig
0.039 Wilcoxon sig
0.040 Mixed model sig
0.040 Mixed model sig
0.043 Mixed model sig
0.044 Mixed model sig
0.046 Mixed model sig
0.046 Mixed model sig
0.050 Mixed model sig
ime points of week 4 and week 1, based on the estimate of the mixed model
Figure 2 Selected metabolites that change during fast-breaking (a-h) and between week one and four (i). Bile acids are given in ng/ml all
other metabolites are given in μM. Time points of sampling are presented on the x-axis and are defined as follows: 1 + 2: collected during first week of
Ramadan (blue), 3 + 4 collected during last fourth of Ramadan (red), 5 collected several weeks after Ramadan (green); 1 + 3 fasting between dawn and
sun set, 2 + 4 after fast-breaking with identical meal, 5 overnight fasting (for plots of all measured parameters see Additional file 4: Figure S1).
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(C18:2 and above). PC levels in the fourth week of
Ramadan were higher than PC levels at the start of
Ramadan, while PC levels at the start of Ramadan were
very similar to those observed after an overnight fast. A
recent study in a cohort of 173 families in Saudi Arabia
showed that approximately two thirds of the respon-
dents (59.5%) reported weight gain after Ramadan [40].
Hence, some of the changes observed in these metabo-
lites may be attributed to a change in nutrition regimen
during Ramadan. Our results clearly suggest that differences
between the effects of short- and long- term fasting, changes
in nutrition pattern, and adaptation of human metabolism
to prolonged fasting conditions can be studied in a suffi-
ciently powered metabolomics study during Ramadan.
Potential for a full-fledged Ramadan study design
Our study was conducted in a small and heterogeneous
group of eleven healthy male individuals with varying BMI,
age and ethnicity and, therefore has considerable limita-
tions. Nevertheless, the experimental design (Figure 1a) we
applied in this proof-of-principle study already revealed
sound metabolic signatures of the pre- and post-prandial
stages as well as the effect of longer-term fasting (several
weeks). Implementation of a full-fledged research study
during the month of Ramadan and collection of additional
phenotype information of the participants may reveal valu-
able information on body adaptation and the plasticity of
metabolic control regarding anabolic/catabolic conditions.
Countries with a large proportion of Muslims in their
population provide an excellent opportunity for such stud-
ies. An example of a sample collection schedule is illus-
trated in Figure 1b. Time series may be collected along the
month of Ramadan and also during a single day, e.g. re-
specting prayer times in order to reliably sample blood
from study participants at different time points. Different
depths of sampling density may be considered, including
use of blood spots rather than venipuncture, and enrol-
ling participants from the medical community at large
clinical centers for more dense sampling protocols.
These individuals may be more easily available for fre-
quent blood sampling. Local communities often organize
joint Iftar festivities in order to break the fast collectively.
Such a set-up can be used for future research studies since
the food consumption can then be monitored and drawing
of samples from volunteers be made at dedicated mobile
sampling and storage units. Furthermore, sample collec-
tion procedures can be simplified and conducted by the
individual at home or work environment via blood spot-
ting on filter paper after finger prick. Metabolic measure-
ments in dried blood spots (DBS), covering a panel of 42
metabolites including acyl-carnitines and amino acids,
were already applied in the clinic to screen infants for
metabolic diseases [41]. The panel of metabolites detectedfrom DBS can be extended to 188 small molecules as pre-
viously described [42]. Such a simplified sampling proced-
ure could also be used in order to increase the number of
samples taken during the day or to allow volunteers taking
samples by themselves during the day without the require-
ment of venipuncture.
One aspect that may need specific consideration is circa-
dian rhythm. During the Ramadan time the sleep patterns
of some individuals may interchange day and night activ-
ities. Therefore, it is extremely important to conduct the
study in a well controlled group of participants, where such
changes are documented and ideally measured. Moreover,
it may be important to document changes in overall activity
pattern, since many Muslims use the Ramadan period to
take vacation and visit family. Notwithstanding, this pilot
study represents a starting basis for the design of a large-
scale Ramadan metabolomics study to address the import-
ant issue of how cultural and religious fasting may affect
metabolism and disease risk in a large group of individuals
with variable preconditions.
Potential for clinical studies
Recently, obesity defined by the World Health Organization
(WHO) as abnormal or excessive fat accumulation that
represents a risk of health [43], reached an epidemic level
by affecting nearly half a billion of the world’s population
[44]. Obesity is recognized as a major risk factor of chronic
diseases, especially cardiovascular disease, hyperglycemia
[45], and type 2 diabetes, [46]. In Arab countries, the preva-
lence of overweight, obesity and type 2 diabetes increased
drastically over the last three decades [47]. Therefore, im-
plementation of a metabolomics study during the month of
Ramadan in countries of dominantly Muslim culture, such
as the Gulf countries, offers the possibility to monitor
large groups of patients with morbid obesity and diabetes
under strictly controlled conditions. A large-scale popula-
tion study on the metabolic regulation during the month
of Ramadan opens several possibilities to explore not only
the metabolic plasticity in healthy individuals, but also to
monitor subjects diagnosed with complex diseases. The
experimental set-up can reveal novel biomarkers for these
diseases, which might only be unmasked under physio-
logical challenge. Furthermore, this study can also be used
for classification of nutrients required for energy produc-
tion and for investigating the proper functioning of the
human body under prolonged fasting in both healthy and
diabetic individuals. The importance of dietary guidelines
to control and reduce the global disease burden including
diet-related complex chronic diseases has already been
emphasized [48].
Last but not least, we like to draw attention to the ad-
vantages of combining metabolomics and genome-wide
association studies (GWAS) in the Arab population during
the month of Ramadan. The capability of GWAS in the
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diovascular disease, as well as with clinically relevant inter-
mediate traits, such as cholesterol and triglyceride levels
has already been reported [49-51]. The first large-scale
metabolomics project including genome wide association
study data (mGWAS) [52] revealed relations between loci
such as FADS1, ELOVL2 or SLC16A9 and changes in spe-
cific lipid species that are products and substrates of these
enzymes and transporters. The advantages of applying
metabolomics together with GWAS to overcome the limi-
tations of GWAS-alone studies was recently discussed
[53,54]. The physiological and metabolic consequences,
with respect to genetic variation analysis, triggered by such
an extreme change in dietary habits (Ramadan) have not
been studied before. Subsequently, by controlling for diet-
ary patterns during the fasting month, we shall be able to
investigate the effect of genetic variations in combination
with various defined nutritional intakes (gene-environment
interaction) on the metabolic profile of the subjects.
Conclusions
By conducting a proof of principle study conducted within
a Muslim community we show that a metabolomics study
during the Holy Month of Ramadan represents a natural
setting that allows to enroll large numbers of study volun-
teers. Albeit based on a small number of individuals, the
here observed changes in metabolite levels are in agree-
ment with previously reported physiological response to
food intake. The Ramadan study design thus provides a
unique opportunity that allows to explore the pre-prandial
and postprandial response of human metabolism to nutri-
tional challenges, especially in defined patient groups that
are otherwise difficult to access under challenge conditions,
such as individuals with type 2 diabetes. We anticipate that
based on the experience gained in this initial small-scale
study, future epidemiology-scale studies on human me-
tabolism under nutritional challenge conditions shall be
conducted.
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